New hope for rare blood disorder when standard treatments fail
NCT ID NCT03933904
Summary
This study tests whether sirolimus, a medication that targets a specific cell pathway, can help adults with a rare blood disorder called idiopathic multicentric Castleman disease (iMCD) when standard treatments haven't worked. Participants take a daily pill for 12 months to see if it reduces symptoms like fatigue and fever while shrinking enlarged lymph nodes. The goal is to control the disease and improve quality of life for those who haven't responded to other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.